Nation-scale adoption of new medicines by doctors: An application of the Bass diffusion model

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Dunn, Adam G ^a   Braithwaite, Jeffrey ^a   Gallego, Blanca ^a   Day, Richard O ^a   Runciman, William ^a,b   Coiera, Enrico ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Adoption; Australia; Decision making; Diffusion of innovation; Evidence based practice; Prescribing behaviour

Indexed keywords

DRUG; NEW DRUG;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HUMAN; MASS COMMUNICATION; THEORETICAL MODEL;

AUSTRALIA; DIFFUSION OF INNOVATION; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84864816998     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-248     Document Type: Article

References (55)

1. Disseminating Innovations in Health Care. Berwick DM, JAMA 2003 289 15 1969 1975 10.1001/jama.289.15.1969 12697800 (Pubitemid 37430229)
2. The $640 Billion Question-Why Does Cost-Effective Care Diffuse So Slowly? Fuchs VR, Milstein A, N Engl J Med 2011 364 21 1985 1987 10.1056/NEJMp1104675 21591938
3. Why the Slow Diffusion of Treatment Guidelines Into Clinical Practice? Kotchen TA, Arch Intern Med 2007 167 22 2394 2395 10.1001/archinte.167.22.2394 18071158 (Pubitemid 350254898)
4. The Diffusion of an Innovation Among Physicians. Coleman J, Katz E, Menzel H, Sociometry 1957 20 4 253 270 10.2307/2785979
5. Coleman J, Katz E, Menzel H, Medical Innovation: A Diffusion Study The Bobbs-Merrill Company, Indianapolis 1966
6. Innovation, Integration, and Marginality: A Survey of Physicians. Menzel H, Am Sociol Rev 1960 25 5 704 713 10.2307/2090143
7. The Diffusion of an Innovation Among Physicians in a Large City. Winick C, Sociometry 1961 24 4 384 396 10.2307/2785920
8. Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up? Bastian H, Glasziou P, Chalmers I, PLoS Med 2010 7 9 1000326 10.1371/journal.pmed.1000326 20877712
9. On the impossibility of being expert. Fraser AG, Dunstan FD, BMJ 2010 341 20959282
10. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL, Nat Rev Drug Discov 2010 9 203 214 20168317
11. The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. Brody H, Light DW, Am J Public Health 2011 101 3 399 404 10.2105/AJPH.2010.199844 21233426
12. Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence. DeAngelis CD, Fontanarosa PB, JAMA 2008 299 15 1833 1835 10.1001/jama.299.15.1833 18413880 (Pubitemid 351549977)
13. Industry sponsorship and selection of comparators in randomized clinical trials. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA, Eur J Clin Invest 2010 40 2 172 182 10.1111/j.1365-2362.2009.02240.x 20050879
14. Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. Lenzer J, BMJ 2011 342 2929 10.1136/bmj.d2929 21558363
15. Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue-Cohort Study. Lundh A, Barbateskovic M, Hrábjartsson A, Gøtzsche PC, PLoS Med 2010 7 10 1000354 10.1371/journal.pmed.1000354 21048986
16. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI, PLoS Med 2010 7 10 1000352 10.1371/journal.pmed.1000352 20976098
17. Local opinion leaders: effects on professional practice and healthcare outcomes. Doumit G, Gattellari M, Grimshaw J, O'Brien MA, Cochrane Database Syst Rev 2007 1 D000125 17253445
18. For and against: Direct to consumer advertising is medicalising normal human experience. Mintzes B, BMJ 2002 324 7342 908 909 10.1136/bmj.324.7342.908 11950745 (Pubitemid 34303948)
19. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. Mintzes B, Barer ML, Kravitz RL, Kazanjian AE, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA, BMJ 2002 324 7332 278 279 10.1136/bmj.324.7332.278 11823361 (Pubitemid 34121841)
20. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Prosser H, Almond S, Walley T, Fam Pract 2003 20 1 61 68 10.1093/fampra/20.1.61 12509373 (Pubitemid 36163787)
21. New drug prescribing by hospital doctors: The nature and meaning of knowledge. Prosser H, Walley T, Soc Sci Med 2006 62 7 1565 1578 10.1016/j.socscimed.2005.08.035 16199121 (Pubitemid 43243257)
22. Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Peay MY, Peay ER, Soc Sci Med 1984 18 12 1019 1025 10.1016/0277-9536(84)90160-6 6463670
23. Patterns of preference for information sources in the adoption of new drugs by specialists. Peay MY, Peay ER, Soc Sci Med 1990 31 4 467 476 10.1016/0277-9536(90)90042-Q 2218627 (Pubitemid 20280401)
24. Diffusion and Social Networks: Revisiting Medical Innovation with Agents. Ratna N, Dray A, Perez P, Grafton R, Newth D, Kompas T, Complex Decision Making 2008 30 247 265
25. The effects of network structure on the provision of healthcare. Dunn AG, Gallego B, Diffusion of competing innovations, The Journal of Artificial Societies and Social Simulation 2010 13 4
26. Managing clinical knowledge for health care improvement. In: Yearbook of Medical Informatics 2000. Balas EA, Boren SA, Patient-Centered Systems Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany, Bemmel J, McCray AT, 65 2000
27. Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. Birkett DJ, McManus P, Br J Clin Pharmacol 1995 40 4 407 410 10.1111/j.1365-2125.1995.tb04565.x 8554945
28. Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, et al. JAMA 2006 295 4 429 433 10.1001/jama.295.4.429 16434633 (Pubitemid 43144979)
29. Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice? Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E, N Engl J Med 1992 327 4 241 247 10.1056/NEJM199207233270405 1535419
30. Impact of Clinical Trial Results on National Trends in -Blocker Prescribing, 1996-2002. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J, JAMA 2004 291 1 54 62 10.1001/jama.291.1.54 14709576 (Pubitemid 38040535)
31. Use of Fibrates in the United States and Canada. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM, JAMA 2011 305 12 1217 1224 10.1001/jama.2011.353 21427374
32. Rogers EM, Diffusion of Innovations Free Press, New York 5 2003
33. Innovation Diffusion and New Product Growth Models in Marketing. Mahajan V, Muller E, J Mark 1979 43 4 55 68 10.2307/1250271
34. New Product Diffusion Models in Marketing: A Review and Directions for Research. Mahajan V, Muller E, Bass FM, J Mark 1990 54 1 1 26 10.2307/1252170
35. Modelling and forecasting the diffusion of innovation-A 25-year review. Meade N, Islam T, Int J Forecast 2006 22 3 519 545 10.1016/j.ijforecast.2006.01. 005 (Pubitemid 44057711)
36. A New Product Growth for Model Consumer Durables. Bass FM, Manag Sci 1969 15 5 215 227 10.1287/mnsc.15.5.215
37. Comments on "A New Product Growth for Model Consumer Durables": The Bass Model. Bass FM, Manag Sci 2004 50 12 1833 1840 10.1287/mnsc.1040.0300 (Pubitemid 40086731)
38. The Impact of Heterogeneity and Ill-Conditioning on Diffusion Model Parameter Estimates. Bemmaor AC, Lee J, Mark Sci 2002 21 2 209 220 10.1287/mksc.21.2.209.151
39. A Diffusion Theory Model of Adoption and Substitution for Successive Generations of High-Technology Products. Norton JA, Bass FM, Manag Sci 1987 33 9 1069 1086 10.1287/mnsc.33.9.1069
40. Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test. van den Bulte C, Stremersch S, Mark Sci 2004 23 4 530 544 10.1287/mksc.1040.0054 (Pubitemid 40024547)
41. Investigating New Product Diffusion across Products and Countries. Talukdar D, Sudhir K, Ainslie A, Mark Sci 2002 21 1 97 114 10.1287/mksc.21.1.97. 161
42. Rosiglitazone: what went wrong? Cohen D, BMJ 2010 341 4848 10.1136/bmj.c4848 20819889
43. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M, Lancet 2004 364 9450 2021 2029 10.1016/S0140-6736(04)17514-4 15582059 (Pubitemid 39593078)
44. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Nissen SE, Wolski K, N Engl J Med 2007 356 24 2457 2471 10.1056/NEJMoa072761 17517853 (Pubitemid 46919772)
45. Failing the Public Health-Rofecoxib, Merck, and the FDA. Topol EJ, N Engl J Med 2004 351 17 1707 1709 10.1056/NEJMp048286 15470193 (Pubitemid 39383201)
46. Entry order as a consideration for innovation strategies. Cohen FJ, Nat Rev Drug Discov 2006 5 4 285 294 10.1038/nrd2009 16531989
47. The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development. DiMasi JA, Paquette C, PharmacoEconomics 2004 22 1 14 15876006 (Pubitemid 39481914)
48. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, Lancet 2006 367 9524 1747 1757 10.1016/S0140-6736(06)68770-9 16731270 (Pubitemid 43767064)
49. Treatment of High Blood Cholesterol in A: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection E, JAMA 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702
50. A Validation of the Bass New Product Diffusion Model in New Zealand. Wright M, Upritchard C, Lewis T, Mark Bull 1997 8 15 29
51. Why the Generalized Bass Model leads to odd optimal advertising policies. Fruchter GE, Van den Bulte C, Int J Res Mark 28 3 218 230
52. Virtual Bass Model and the left-hand data-truncation bias in diffusion of innovation studies. Jiang Z, Bass FM, Bass PI, Int J Res Mark 2006 23 1 93 106 10.1016/j.ijresmar.2006.01.008 (Pubitemid 43399680)
53. Bias and Systematic Change in the Parameter Estimates of Macro-Level Diffusion Models. van den Bulte C, Lilien GL, Mark Sci 1997 16 4 338 353 10.1287/mksc.16.4.338
54. Opinion Leadership and Social Contagion in New Product Diffusion. Iyengar R, Van den Bulte C, Valente TW, Mark Sci 2011 30 2 195 212 10.1287/mksc.1100. 0566
55. Why system inertia makes health reform so difficult. Coiera E, BMJ 2011 342 3693 10.1136/bmj.d3693 21700652